{"id":260364,"date":"2024-04-08T16:04:11","date_gmt":"2024-04-08T08:04:11","guid":{"rendered":"http:\/\/www.namnewsnetwork.org\/?p=260364"},"modified":"2024-04-08T16:04:12","modified_gmt":"2024-04-08T08:04:12","slug":"curium-plans-to-significantly-expand-lutetium-177-capacity-and-pet-footprint-with-agreement-to-acquire-eczacibasi-monrol","status":"publish","type":"post","link":"http:\/\/namnewsnetwork.org\/?p=260364","title":{"rendered":"Curium Plans To Significantly Expand Lutetium-177 Capacity And Pet Footprint With Agreement To Acquire Eczaciba\u015fi-Monrol"},"content":{"rendered":"\n<p><strong>PARIS, April 8 (Bernama-GLOBE NEWSWIRE) &#8212;&nbsp;<\/strong>Curium, a world leader in nuclear medicine, announced today that it has entered into an agreement with Eczac\u0131ba\u015f\u0131 Holding and Bozlu Group for the acquisition of Eczac\u0131ba\u015f\u0131-Monrol Nuclear Product Co. (Monrol), a dedicated specialist in nuclear medicine. The acquisition is expected to bring together highly complementary geographical footprints, lutetium-177 (Lu-177) capabilities, and PET &amp; SPECT nuclear medicine infrastructure, as well as facilitate the development of cutting-edge radionuclides and radiopharmaceuticals pipelines for diagnostic and therapeutic purposes.<\/p>\n\n\n\n<p>Importantly, the acquisition will add significant Lu-177 manufacturing capacity to Curium to meet the growing demand for Lu-177 around the world for the benefit of more than 100,000 critically ill patients worldwide over the next five years. It will expand Curium\u2019s PET footprint of 34 sites in Western Europe and Asia with the addition of 12 owned and partnered sites in Eastern Europe and MENA regions. In addition, Eczac\u0131ba\u015f\u0131-Monrol\u2019s manufacturing and logistics infrastructure in Istanbul, Turkey, will add significant scale to Curium\u2019s vertically integrated production and distribution capabilities.<\/p>\n\n\n\n<p><a href=\"http:\/\/mrem.bernama.com\/viewsm.php?idm=48326\">http:\/\/mrem.bernama.com\/viewsm.php?idm=48326<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>PARIS, April 8 (Bernama-GLOBE NEWSWIRE) &#8212;&nbsp;Curium, a world leader in nuclear medicine, announced today that it has entered into an agreement with Eczac\u0131ba\u015f\u0131 Holding and Bozlu Group for the acquisition of Eczac\u0131ba\u015f\u0131-Monrol Nuclear Product Co. (Monrol), a dedicated specialist in nuclear medicine. The acquisition is expected to bring together highly complementary geographical footprints, lutetium-177 (Lu-177) [&hellip;]<\/p>\n","protected":false},"author":14,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":[],"categories":[315],"tags":[],"_links":{"self":[{"href":"http:\/\/namnewsnetwork.org\/index.php?rest_route=\/wp\/v2\/posts\/260364"}],"collection":[{"href":"http:\/\/namnewsnetwork.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"http:\/\/namnewsnetwork.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"http:\/\/namnewsnetwork.org\/index.php?rest_route=\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"http:\/\/namnewsnetwork.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=260364"}],"version-history":[{"count":1,"href":"http:\/\/namnewsnetwork.org\/index.php?rest_route=\/wp\/v2\/posts\/260364\/revisions"}],"predecessor-version":[{"id":260365,"href":"http:\/\/namnewsnetwork.org\/index.php?rest_route=\/wp\/v2\/posts\/260364\/revisions\/260365"}],"wp:attachment":[{"href":"http:\/\/namnewsnetwork.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=260364"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"http:\/\/namnewsnetwork.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=260364"},{"taxonomy":"post_tag","embeddable":true,"href":"http:\/\/namnewsnetwork.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=260364"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}